Cellevate strengthens management team with the appointment of Dr. Christel Fenge as Chief Technology Officer
Lund, Sweden, 12 March 2025 – Cellevate AB, an innovative biotech company developing next-generation cell culture solutions to revolutionize biomanufacturing, is pleased to announce the appointment of Dr. Christel Fenge as Chief Technology Officer (CTO) and member of the management team.
Dr. Fenge, who has served as a Strategic Advisor to Cellevate since June 2024, brings over 30 years of experience in leadership roles within the bioprocessing and biopharmaceutical industries. Previous positions include VP, R&D Bioprocess at Cytiva and VP, Marketing & Product Management at Sartorius, overseeing upstream and downstream development and commercialization. This expertise will be instrumental in scaling up Cellevate’s groundbreaking nanofiber-based cell culture products.
“I am delighted to take on the role of CTO at Cellevate,” says Dr. Christel Fenge. “The company’s commercially available nanofiber-based cell culture systems have already shown great potential in biomanufacturing, and I look forward to supporting the team as we now have moved into commercialization and scale-up.”
“Bringing Dr. Fenge into the management team strengthens our ability to accelerate the commercialization and the strategic partnerships with customers and turnkey solution providers in bioprocessing,” says Laura Chirica, CEO of Cellevate. “Her deep expertise in upstream bioprocessing, combined with strategic leadership, will be invaluable as we continue to commercialize and implement Cellevat3d® nanofiber cell culture solutions in new therapeutic large-scale applications, develop new product families and position our company as a proven provider in this industry.”
More information about Cellevate’s management team can be found on our website.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.
For more information, please visit www.cellevate.com.